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Co-ctmTtmm of monocytes (MO) and endothelial
cells (EC) were studied for their capacity to
synergize in the production of interleukin-6 (IL-6)
and granulocyte-macrophage colony-stimulating
factor (GM-CSF), two cytokines potentially
important in vascular physiopathology. Resting
monocytes produced detectable amounts of IL-6
but no GM-CSF, whereas confluent EC produced
significant quantities of GM-CSF, but minimal IL-
6. In co-cultures without stimuli, additive synth-
esis of both cytokines was observed. When EC
were pretreated, however, with either PAF, TNF
or both stimuli, before addition of MO, synergis-
tic production of IL-6 was observed. In contrast,
GM-CSF production was not enhanced by co-
culture of monocytes with activated EC. When
either cell population was fixed with para-
formaldehyde or killed by freeze-thawing before
addition to the co-culture, cytokine levels
reverted to those produced by the unaffected
population alone. On the other hand, separating
the two cell populations by a cell-impermeable
membrane in transwell cultures did not affect the
synergistic production of the cytokines. Taken
together, our data suggest that EC and MO can
synergize in response to stimuli by producing IL-
6 and that this synergy is dependent on the
integrity of both cell populations, but indepen-
dent of cell-cell contact.
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Introduction
Vascular endothelium interacts closely with
leukocytes and constitutes an important cellular
element in inflammatory and immunologic
responses. This interaction is in part regulated
by cytokines and several other mediators derived
from leukocytes which act on endothelial cells
(EC).2-4 Among these, platelet-activating factor
(PAF) can be produced by a variety of cells such
as monocytes, neutrophils and endothelial
cells.5- This phospholipid is a potent pro-inflam-
matory mediator and causes a variety of effects,
including microvascular leakage, contraction of
smooth muscle and activation of neutrophils,
macrophages and eosinophils.
9- We have
demonstrated that PAF can induce suppressor cell
activities in mononuclear leukocytes in vitro,
]2’13
as well as stimulate IL-1, TNF and IL-6 production
in monocytes and alveolar macrophages.4’5 In
cultured human EC, PAF was shown to induce
shape changes, release of prostacyclin and vasodi-
1617 k r latation. PAF is also proposed as a ey playe
in leukocyte adhesion to the endothelium by
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tethering leukocytes and inducing subsequent
activation and adhesion stages.
Interleukin-6 (IL-6) has been shown to be a
multifunctional cytokine that regulates, among
other things, immune responses, acute phase
reactions and haematopoiesis. It has also been
reported to induce EC proliferation.
9 IL-6 is syn-
thesized by EC following stimulation with IL-1,
LPS or TNF-(,
2-22 but other cells also produce
IL-6, including monocytes, macrophages and
fibroblasts.23-26
EC can also synthesize GM-CSF, either con-
stitutively or more commonly after stimulation
with IL-12v-31 or TNF.32 The production of GM-
33 34 CSF by fibroblasts, T lymphocyt.es, mast
35 36 cells and monocytes/macrophages has also
been demonstrated. GM-CSF is an important gly-
coprotein in the interaction of leukocytes with
EC since it jromotes the adherence of mono-
cytes to EC, augments accessory cell function
of monocytes and stimulates certain monocyte
effector activities involved in microbial and
tumoricidal killing.8 In the present work, we
examined the potential synergy between EC and
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monocytes in their production of IL-6 and GM- coated flasks42 for 60 min at 37C. After removal
CSF, using a co-culture system, of nonadherent cells, containing 95-98% lympho-
cytes, the adherent cells were further incubated
Materials and Methods for 20 min at 37C in the presence of mono-
sodium EDTA and medium (1:1). This procedure
Reagents: PAF (1-O-alkyl-2-acetyl-sn-glycero-3- yielded a cell population consisting of more than
phosphocholine) was obtained from Bachem 95% pure monocytes as determined by non-
Fine Chemicals (Torrance, CA); TNF-a was pur- specific esterase staining.
chased from Amersham and indomethacin was
obtained from Sigma Chemical Co. (St Louis, Endothelial cells and monocyte co-cultures: Con-
MO). fluent EC were detached from flasks, washed and
resuspended in Iscove medium containing 5%
Isolation of endothelial cells: EC were isolated FBS. Aliquots of 0.2 x 10 EC were preincubated
from human umbilical vein as described pre- for 24h with either medium or graded con-
viously.39’40 Briefly, umbilical veins from indivi- centrations of PAF. EC were then washed and
dual cords were cannulated, washed with PBS, incubated in the presence or absence of TNF-a
disodium EDTA (5 x 10-4M; Sigma, St Louis, (25U/ml) and indomethacin (1 M) for 4h in
MO), and treated with 0.2% collagenase type V Iscove medium supplemented with 0.25% BSA.
(Sigma) in PBS. After an incubation of 20 min at Cells were washed again and incubated with
37C, detached cells were collected by washing 1 x 10 monocytes in Iscove medium containing
twice with PBS, centrifuged and resuspended in 5% FBS. After a 24h co-culture, cell-free super-
complete medium consisting of Iscove medium natants were harvested and assayed for the
(Flow, McLean, VA) supplemented with 10% presence of IL-6 and GM-CSF. In preliminary
heat-inactivated foetal bovine serum (FBS, Flow), experiments, these conditions were found to be
penicillin (167U/ml), streptomycin (2001.tg/ml), optimal for cytokine production.
amphotericin B (4 I.tg/ml), and 37.5 l.tg/ml EC
growth supplement (CR-ECGS; Collaborative IL-6 and GM-CSF assay: The activity of IL-6 was
Research Inc., Lexington, MA). These primary determined using IL-6-dependent cells of the
culture cells were plated on 75-cm
2 tissue culture murine hybridoma cell line B9 as described.43’44
flasks (Falcon Oxnard, CA), fed three times a Briefly, serially diluted samples were dispensed
week and usually became confluent in 4-7 days. into fiat-bottomed 96-well microtitre plates
When cultures reached confluence, flasks were (Limbro, McLean, MO). B9 cells, resuspended in
rinsed with disodium EDTA and then incubated RPMI 1640 medium + 5% FBS and 5 x 10-5M
for 2-3 min with EDTA containing 0.05% trypsin 2-mercaptoethanol, were added (5 x 103 cells/
(Gibco, Grand Island, NY) to detach the cells, well) and the plates were incubated at 37C for
EC were washed, resuspended in complete 72 h. Proliferation of B9 cells was measured by a
medium and seeded in flasks precoated with colorimetric assay using MTT (5mg/ml; Sigma).
0.1% gelatin (Sigma)in Iscove medium. Plates were then read at 595nm using the
EC were characterized by the detection of BioRad Microplate Reader (BioRad, Richmond,
factor VIII-like antigen (von Willebrand’s factor) CA). The activity of IL-6 in test supernatants was
by indirect immunofluorescence performed with calculated on the basis of cellular growth
a rabbit anti-vW factor antiserum (Calbiochem obtained in the presence of various concentra-
Behring, La Jolla, CA). tions of a rIL-6 standard, using probit analysis of
dilution curve data. Immunoreactive human GM-
Preparation of monocytes.. Peripheral blood was CSF was measured using the enzyme-linked
collected from healthy volunteers by veni- immunosorbent assay (ELISA), commercially
puncture, diluted in PBS and underlaid with available from R&D Systems (Minneapolis, MN).
41 Ficoll-Hypaque (Ficoll 400, Pharmacia,
Uppsala, Sweden; Hypaque sodium, Winthrop Results Laboratories, Aurora, Ontario). After centrifuga-
tion for 30 min at 400 x g at room temperature, Unstimulated EC produced minimal quantities
peripheral blood mononuclear leukocytes of IL-6, and their stimulation with TNF-a (25 U/
(PBML) were collected at the interface, washed ml) had a negligible effect (Fig. 1). In contrast,
twice in PBS and resuspended in Iscove medium unstimulated monocytes produced significant
containing 10% FBS and antibiotics. The cell. sus- amounts of IL-6. When these monocytes were co-
pension was composed of approximately 75-85% cultured with resting EC, an additive effect was
lymphocytes and 15-20% monocytes. Monocytes observed. In contrast, when they were co-cul-
were separated by adherence to microexsudate- tured with TNF-treated EC, a synergistic three-
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FIG. 1. Synthesis of IL-6 by endothelial cell (EC), monocytes (MO)
or co-cultures of both EC and MO. EC were treated for 4 h with
either medium or TNF- (25U/ml), washed and incubated for
24h alone or with unstimulated MO. Cultures of monocytes
alone were incubated for 24 h in medium. Cell-free supernatants
were then collected and IL-6 activity was measured by the B9
cell proliferation assay. Data represent mean -!- S.EoM. of seven
to 14 experiments. Statistically significant effects were noted as:
*p < 0.005; **p < 0.0005. Pretreatment of EC: [], medium;,
PAF and TNF.
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FIG. 2. Effect of PAF on IL-6 production by EC:MO co-cultures.
EC were preincubated in the absence or presence of graded
concentrations of PAF for 24 h, washed and exposed to medium
or TNF- (25 U/ml) for 4h. After washing, EC were co-cultured
with unstimulated monocytes for 24h. Cell-free supernatants
were then harvested for measurement for IL-6 activity. Data
represent mean -t- S.E.M. of four to 12 experiments. Statistically
significant effects were noted as: *p < 0.05. I--, with TNF; <,
without TNF.
fold stimulation of IL-6 production was observed
(Fig. 1).
Since PAF is involved in leukocyte-EC interac-
tions, we examined whether PAF could modulate
IL-6 production in EC-MO co-cultures. EC were
pretreated with graded concentrations of PAF
(10-16-10-6M) before addition of monocytes.
As shown in Fig. 2, PAF alone was at least as
effective as TNF alone in stimulating IL-6 produc-
tion in the co-cultures, with a maximal effect at
10-M PAF. When EC were pretreated with PAF
and subsequently stimulated with TNF, their co-
culture with monocytes resulted in a synergistic
six-fold enhancement of IL-6 production.
In order to analyse the cellular requirements
for the synergistic response to PAF and TNF, co-
cultures were compared to EC or MO popula-
tions alone, as well as to co-cultures in which
one of the cell populations was either killed by
freeze-thawing (to preserve membrane struc-
tures) or fixed by paraformaldehyde treatment.
As shown in Fig. 3, killed or fixed EC could no
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longer synergize with MO and IL-6 production
reverted to that of MO alone. Similarly, killed or
fixed MO could no longer synergize with EC and
IL-6 levels fell to the minimal production
observed with EC alone.
In contrast to IL-6, GM-CSF production was
mainly observed in resting or stimulated EC,
whereas monocytes alone produced negligible
quantities of the cytokine (Fig. 4). Enhanced
synthesis of GM-CSF was observed in co-cultures
of untreated EC and MO but, whereas stimulated
EC alone showed doubling of their GM-CSF pro-
duction, addition of MO to stimulated EC had no
further effect. The main cellular source of GM-
CSF production was made evident in the co-cul-
tures with one cell population killed by freeze-
thawing or fixed with paraformaldehyde. Co-cul-
tures of intact MO with fixed or killed EC
showed little GM-CSF production, whereas co-
cultures of intact EC with killed or fixed MO had
responses similar to those of EC alone.Monocyte-endothelial cell synergy in cytokine production
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FIG. 3. Effect of prior lysis or fixation of either cell population on
the production of IL-6 by EC:MO co-cultures. After treatment for
24h with either medium or PAF (10-1M)+TNF- (25U/ml),
EC were washed and either fixed with paraformaldehyde
(0.05%) for 30 min, or lysed by three cycles of freezing (liquid
nitrogen) and thawing (37C). Thereafter EC were washed and
incubated with monocytes. Alternatively, monocytes were fixed
or lysed in the same manner and then washed and added to
intact EC. After 24h of co-culture, cell-free supernatants were
harvested and assayed for IL-6 activity. Data represent mean -t-
S.E.M. of three experiments. Statistically significant effects were
noted as: *p < 0.0001" **p < 0.0005, in comparison to mono-
cytes alone. ,, Medium; [], TNF.
Because synergy in IL-6 production was depen-
dent on live and fully functional MO and EC, and
intact membranes did not substitute for live cells,
we tested the requirement for actual cell-cell
contact for the observed synergistic response.
We used Costar transwell culture vessels in
which MO were separated from EC by a poly-
carbonate, cell-impermeable membrane. As
shown in Table 1, synergy in IL-6 production was
maintained in spite of the physical separation of
the two cell populations.
Discussion
Our studies described here present evidence
for contact-independent synergy in production of
IL-6 by co-cultures of human MO and EC.
Maximal effects were observed when resting MO
were added to PAF-primed and TNF-treated EC,
## #_T_#
FIG. 4. Effect of prior lysis or fixation of either cell population on
the production of GM-CSF by EC:MO co-cultures. After treat-
ment for 24h with either medium or PAF (10-1M)+TNF-
(25 U/ml), EC were washed and either fixed with paraformalde-
hyde (0.05%) for 30 min, or lysed by three cycles of freezing
(liquid nitrogen) and thawing (37C). Thereafter EC were washed
and incubated with monocytes. Alternatively, monocytes were
fixed or lysed in the same manner and then washed and added
to intact EC. After 24 h of co-culture, cell-free supernatants were
harvested and assayed for GM-CSF activity. Data represent
mean -t- S.E.M. of three experiments. Statistically significant
effects were noted as: *p < 0.005; #p < 0.0005, in comparison
to EC alone. ,, Medium; [], PAF and TNF.
but a significant concentration-dependent
enhancement of IL-6 production was also
observed in co-cultures of MO and EC, when the
latter were pretreated with PAF alone.
Since PAF can induce its own synthesis in EC45
and since we have shown PAF to stimulate IL-6
production in EC, monocytes and alveolar
46 47 macrophages, it is possible that the observed
synergy may be due, in part, to the action of de
novo synthesized, EC-derived PAF and MO. This
is unlikely, however, since EC retain most of the
synthesized PAF in a cell-associated form and
cell-cell contact was shown not to be necessary
for the observed synergy. Moreover, EC mem-
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Table 1. Contact-independent synergy of EC and MO in IL-6
production
Cells IL-6 (U/ml)
EC alone
medium 1200 ___
50
PAF +TNF 3020 ___
400
MO alone 16200 -t- 4800
MO + EC
medium 43600 + 6440
PAF +TNF 62100 _
5200 (p < 0.05)
MO + EC/transwells
medium 40400 ___
2200
PAF+TNF 52800 -t- 1100 (p< 0.02)
EC were preincubated with medium or PAF (10-1M)+TNF- (25U/ml)
as indicated in Materials and Methods and thereafter either cultured
alone or with unstimulated MO. Alternatively, EC were cultured in Costar
transwells, separated from MO by a cell-impermeable polycarbonate
membrane. After 24 h of culture, cell-free supernatants were harvested
for assays of IL-6 content. Supernatants from either side of the transwell
membrane had equivalent contents of IL-6.
branes alone were not sufficient to trigger MO
synthesis of IL-6, as demonstrated by the freeze-
thaw experiments: MO cultured with lysed, but
otherwise intact PAF-primed EC produced no
more IL-6 than MO alone.
In contrast to IL-6, GM-CSF production was
mainly derived from EC and their stimulation
with PAF and TNF resulted in enhanced produc-
tion of the cytokine. Since GM-CSF can increase
IL-6 production by monocytes,2 it remains to be
tested whether GM-CSF plays a role in the
synergy in IL-6 production observed in our co-
cultures. The transwell experiments suggest that
a soluble factor from either of the two cell types,
or from both cell types, is essential for the up-
regulated production of cytokines. Further
studies will help determine the nature of such
factor(s).
In summary, exposure to EC and the inflam-
matory stimuli PAF and TNF resulted not only in
their enhanced production of GM-CSF, but also
in their ability to synergize with MO in aug-
mented IL-6 production. Interestingly, this
synergy did not require cell-cell contact between
EC and MO, in contrast to many other synergistic
events which depend on cell contact and involve
various combinations of cell adhesion molecules.
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